Relevant bibliographies by topics / Immune checkpoint inhibitors (ICIs)

Academic literature on the topic 'Immune checkpoint inhibitors (ICIs)'

Author: Grafiati
Published: 10 December 2022
Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Immune checkpoint inhibitors (ICIs).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Immune checkpoint inhibitors (ICIs)"

1

Farshidpour, Maham, and William Hutson. "Immune Checkpoint Inhibitors Induced Hepatotoxicity; Gastroenterologists’ Perspectives." Middle East Journal of Digestive Diseases 14, no. 2 (April 30, 2022): 244–53. http://dx.doi.org/10.34172/mejdd.2022.279.

Full text
Abstract:
BACKGROUND: Immune checkpoint inhibitors (ICIs) have promising clinical activity and are essential medications for patients with several malignancies. However, by deranging the immune system, these novel agents could lead to immune-related adverse events (IRAEs). Hepatotoxicity with checkpoint inhibitors usually results in acute hepatitis or drug-induced liver injury. METHODS: This review article discusses the recent clinical evidence available regarding checkpoint inhibitor-induced hepatitis and reviews an approach to their diagnosis and management. CONCLUSION: ICIs have improved patients’ outcomes with different forms of malignancy; however, ICIs-related liver damage is a clinically significant entity in these patients. All patients should be monitored carefully for IRAEs while undergoing treatment with ICIs.
APA, Harvard, Vancouver, ISO, and other styles
2

Shiravand, Yavar, Faezeh Khodadadi, Seyyed Mohammad Amin Kashani, Seyed Reza Hosseini-Fard, Shadi Hosseini, Habib Sadeghirad, Rahul Ladwa, Ken O’Byrne, and Arutha Kulasinghe. "Immune Checkpoint Inhibitors in Cancer Therapy." Current Oncology 29, no. 5 (April 24, 2022): 3044–60. http://dx.doi.org/10.3390/curroncol29050247.

Full text
Abstract:
The discovery of immune checkpoint proteins such as PD-1/PDL-1 and CTLA-4 represents a significant breakthrough in the field of cancer immunotherapy. Therefore, humanized monoclonal antibodies, targeting these immune checkpoint proteins have been utilized successfully in patients with metastatic melanoma, renal cell carcinoma, head and neck cancers and non-small lung cancer. The US FDA has successfully approved three different categories of immune checkpoint inhibitors (ICIs) such as PD-1 inhibitors (Nivolumab, Pembrolizumab, and Cemiplimab), PDL-1 inhibitors (Atezolimumab, Durvalumab and Avelumab), and CTLA-4 inhibitor (Ipilimumab). Unfortunately, not all patients respond favourably to these drugs, highlighting the role of biomarkers such as Tumour mutation burden (TMB), PDL-1 expression, microbiome, hypoxia, interferon-γ, and ECM in predicting responses to ICIs-based immunotherapy. The current study aims to review the literature and updates on ICIs in cancer therapy.
APA, Harvard, Vancouver, ISO, and other styles
3

Gan, Jiadi, Yihua Huang, Wenfeng Fang, and Li Zhang. "Research progress in immune checkpoint inhibitors for lung cancer in China." Therapeutic Advances in Medical Oncology 13 (January 2021): 175883592110298. http://dx.doi.org/10.1177/17588359211029826.

Full text
Abstract:
Immune checkpoint inhibitors (ICIs) have come to play an increasingly prominent role in the treatment of lung cancer, and some are recommended as a first-line treatment for late-stage non-small-cell lung cancer, either as a monotherapy or in combination with chemotherapy. Accordingly, the indications of Food and Drug Administration-approved ICIs have increased. In this background, China has implemented various policies to encourage and accelerate the marketing of domestic and imported innovative antitumor drugs. Eight ICIs have been approved in China. Among these, four imported programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors have received approval for six indications, and one domestic PD-1 inhibitor has received approval for one indication for lung cancer in 2018. Numerous clinical trials of ICIs for lung cancer are underway in China. This review aims to summarize the recent advances and future directions of ICIs, including PD-1 inhibitors, PD-L1 inhibitors, cytotoxic T lymphocyte-associated antigen-4 inhibitors, bi-specific antibodies, and a novel inhibitor of T-cell immune-receptor with Ig and immunoreceptor tyrosine-based inhibitory motif domains in immunotherapies for lung cancer in China.
APA, Harvard, Vancouver, ISO, and other styles
4

Makaremi, Shima, Zahra Asadzadeh, Nima Hemmat, Amir Baghbanzadeh, Alessandro Sgambato, Farid Ghorbaninezhad, Hossein Safarpour, et al. "Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects." Biomedicines 9, no. 9 (August 24, 2021): 1075. http://dx.doi.org/10.3390/biomedicines9091075.

Full text
Abstract:
Immunotherapy is a new pillar of cancer therapy that provides novel opportunities to treat solid tumors. In this context, the development of new drugs targeting immune checkpoints is considered a promising approach in colorectal cancer (CRC) treatment because it can be induce specific and durable anti-cancer effects. Despite many advances in the immunotherapy of CRC, there are still limitations and obstacles to successful treatment. The immunosuppressive function of the tumor microenvironment (TME) is one of the causes of poor response to treatment in CRC patients. For this reason, checkpoint-blocking antibodies have shown promising outcomes in CRC patients by blocking inhibitory immune checkpoints and enhancing immune responses against tumors. This review summarizes recent advances in immune checkpoint inhibitors (ICIs), such as CTLA-4, PD-1, PD-L1, LAG-3, and TIM-3 in CRC, and it discusses various therapeutic strategies with ICIs, including the double blockade of ICIs, combination therapy of ICIs with other immunotherapies, and conventional treatments. This review also delineates a new hopeful path in the combination of anti-PD-1/anti-PD-L1 with other ICIs such as anti-CTLA-4, anti-LAG-3, and anti-TIM-3 for CRC treatment.
APA, Harvard, Vancouver, ISO, and other styles
5

Moshirfar, Majid, Noor F. Basharat, Tanner S. Seitz, Briana K. Ply, Yasmyne C. Ronquillo, and Phillip C. Hoopes. "Corneal Transplant Rejections in Patients Receiving Immune Checkpoint Inhibitors." Journal of Clinical Medicine 11, no. 19 (September 25, 2022): 5647. http://dx.doi.org/10.3390/jcm11195647.

Full text
Abstract:
Immune checkpoint inhibitors (ICIs) are antibodies that target and block immune checkpoints. These biologics were initially approved by the United States Food and Drug Administration (US FDA) in 2011 for the management of melanoma. Since then, the use of ICI therapy has increased, with many new medications on the market that treat approximately 50 types of cancers. Patients receiving this therapy are at an increased risk for transplant rejection, including corneal rejection. Ophthalmologists must be aware of individuals receiving ICI therapy as it may be a relative contraindication for patients with a history of corneal transplantation. Patients on ICIs may also experience ocular side effects, including uveitis, dry eye, and inflammation, while on checkpoint inhibitor therapy. This commentary discusses the current understanding of immune checkpoint inhibitors, their mechanism of action, their ocular side effects, and their role in corneal transplant rejection.
APA, Harvard, Vancouver, ISO, and other styles
6

Kwon, Hyemi, Eun Roh, Chang Ho Ahn, Hee Kyung Kim, Cheol Ryong Ku, Kyong Yeun Jung, Ju Hee Lee, et al. "Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society." Endocrinology and Metabolism 37, no. 6 (December 31, 2022): 839–50. http://dx.doi.org/10.3803/enm.2022.1627.

Full text
Abstract:
Immune checkpoint inhibitors (ICIs) including an anti-cytotoxic T-lymphocyte-associated antigen 4 inhibitor, anti-programmed cell death protein 1 (PD-1) inhibitors, and anti-PD-ligand 1 inhibitors are representative therapeutics for various malignancies. In oncology, the application of ICIs is currently expanding to a wider range of malignancies due to their remarkable clinical outcomes. ICIs target immune checkpoints which suppress the activity of T-cells that are specific for tumor antigens, thereby allowing tumor cells to escape the immune response. However, immune checkpoints also play a crucial role in preventing autoimmune reactions. Therefore, ICIs targeting immune checkpoints can trigger various immune-related adverse events (irAEs), especially in endocrine organs. Considering the endocrine organs that are frequently involved, irAEs associated endocrinopathies are frequently life-threatening and have unfavorable clinical implications for patients. However, there are very limited data from large clinical trials that would inform the development of clinical guidelines for patients with irAEs associated endocrinopathies. Considering the current clinical situation, in which the scope and scale of the application of ICIs are increasing, position statements from clinical specialists play an essential role in providing the appropriate recommendations based on both medical evidence and clinical experience. As endocrinologists, we would like to present precautions and recommendations for the management of immune-related endocrine disorders, especially those involving the adrenal, thyroid, and pituitary glands caused by ICIs.
APA, Harvard, Vancouver, ISO, and other styles
7

Nardi Agmon, Inbar, Osnat Itzhaki Ben Zadok, and Ran Kornowski. "The Potential Cardiotoxicity of Immune Checkpoint Inhibitors." Journal of Clinical Medicine 11, no. 3 (February 7, 2022): 865. http://dx.doi.org/10.3390/jcm11030865.

Full text
Abstract:
The use of immune checkpoint inhibitors (ICIs) as a mono- or adjuvant oncologic treatment is rapidly expanding to most fields of cancer. Alongside their efficacy, ICIs carry the risk of immune-related adverse events (irAEs) arising from misguided immune-mediated response to normal tissues. In the cardiovascular system, the cardiac toxicity of ICIs has been primarily related to the development of an acute, immune-mediated myocarditis; beyond this potentially fatal complication, evidence of an increased risk of cardiovascular events and accelerated atherosclerosis is emerging, as well as reports of other cardiovascular adverse events such as arrythmias, Takotsubo-like syndrome and vascular events. The absence of identified risk factors for cardiotoxic complications, specific monitoring strategies or diagnostic tests, pose challenges to the timely recognition and optimal management of such events. The rising numbers of patients being treated with ICIs make this potential cardiotoxic effect one of paramount importance for further investigation and understanding. This review will discuss the most recent data on different cardiotoxic effects of ICIs treatment.
APA, Harvard, Vancouver, ISO, and other styles
8

Hamada, Kazuyuki, Takuya Tsunoda, and Kiyoshi Yoshimura. "Emerging Immune-Monitoring System for Immune Checkpoint Inhibitors." Life 12, no. 8 (August 13, 2022): 1229. http://dx.doi.org/10.3390/life12081229.

Full text
Abstract:
Immune checkpoint inhibitors (ICIs) have a major impact on cancer treatment. However, the therapeutic efficacy of ICIs is only effective in some patients. Programmed death ligand 1 (PD-L1), tumor mutation burden (TMB), and high-frequency microsatellite instability (MSI-high) are markers that predict the efficacy of ICIs but are not universally used in many carcinomas. The gut microbiota has received much attention recently because of its potential to have a significant impact on immune cells in the cancer microenvironment. Metabolites of the gut microbiota modulate immunity and have a strong influence on the therapeutic efficacy of ICI. It has been suggested that the gut microbiota may serve as a novel marker to predict the therapeutic efficacy of ICI. Therefore, there is an urgent need to develop biomarkers that can predict anti-tumor effects and adverse events, and the study of the gut microbiota is essential in this regard.
APA, Harvard, Vancouver, ISO, and other styles
9

Sun, Yining, Nan Wang, and Nuo Zhang. "Immune Checkpoint inhibitor Therapy in Various Cancers." Highlights in Science, Engineering and Technology 14 (September 29, 2022): 318–23. http://dx.doi.org/10.54097/hset.v14i.1840.

Full text
Abstract:
Immune checkpoint inhibitors (ICIs) are a new way of immunotherapy, not simply refers to the improvement of immunity to the body, but by improving the immune microenvironment around the tumor, thereby activating immune cell activity in vivo to achieve anti-tumor purposes. Now, CTLA‐4 and PD‐1 or PD‐L1 monoclonal antibody are mainly developed relatively successfully for immune checkpoints, in addition to other new immune checkpoints that have been discovered and clinically tested. However, while immune checkpoint inhibitors have been developed successively, some vague problems still need to be solved, such as the large gap between the immunotherapy effects of different patients. These issues are critical to the selection of immune checkpoint inhibitors. In this review, based on the study of the immunosuppressive mechanism of CTLA-4 and PD-1/PD-L1, the application of related immune checkpoint inhibitors in cancer treatment is discussed starting from three representative types of cancer. At the same time, according to the existing problems, some common immune-related adverse events and newly discovered immune checkpoints are summarized, and the future research direction of ICIs is further explored.
APA, Harvard, Vancouver, ISO, and other styles
10

Mazloom, Anita, Nima Ghalehsari, Victor Gazivoda, Neil Nimkar, Sonal Paul, Peter Gregos, Janice Rateshwar, and Uqba Khan. "Role of Immune Checkpoint Inhibitors in Gastrointestinal Malignancies." Journal of Clinical Medicine 9, no. 8 (August 6, 2020): 2533. http://dx.doi.org/10.3390/jcm9082533.

Full text
Abstract:
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of several solid and hematological malignancies. ICIs are not only able to produce long and durable responses, but also very well tolerated by patients. There are several approved indications of use of ICIs in treatment of metastatic gastrointestinal malignancies including gastric, esophageal, colorectal and hepatocellular carcinoma. In addition, ICIs can be used in microsatellite instability-high (MSI-H) and high tumor mutational burden (TMB) tumors in chemotherapy-resistant setting. Despite having good efficacy and superior safety profile, ICIs are clinically active in small subset of patients, therefore, there is a huge unmet need to enhance their efficacy and discover new predictive biomarkers. There are several ongoing clinical trials that are exploring the role of ICIs in various gastrointestinal cancers either as single agent or in combination with chemotherapy, radiation therapy, targeted agents or other immunotherapeutic agents. In this review, we discuss the published and ongoing trials for ICIs in gastrointestinal malignancies, including esophageal, gastric cancer, pancreatic, hepatocellular, biliary tract, colorectal and anal cancers. Specifically, we focus on the use of ICIs in each line of therapy and discuss the future directions of these agents in each type of gastrointestinal cancer.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Immune checkpoint inhibitors (ICIs)"

1

Khunger, Monica, Sagar Rakshit, Adrian V. Hernandez, Vinay Pasupuleti, Kate Glass, Matthew D. Galsky, and Petros Grivas. "Premature clinical trial discontinuation in the era of immune checkpoint inhibitors." Wiley-Blackwell, 2018. http://hdl.handle.net/10757/624716.

Full text
Abstract:
El texto completo de este trabajo no está disponible en el Repositorio Académico UPC por restricciones de la casa editorial donde ha sido publicado.
Background: Clinical trial completion is critical for new cancer therapies. Premature trial termination or withdrawal is common and impairs progress. We assessed factors of early terminated/withdrawn oncology trials focusing on trials with immune checkpoint inhibitors (ICI), hypothesizing that the latter may be associated with lower rates of premature discontinuation. Materials and Methods: We reviewed all adult, intervention, oncology trials registered in ClinicalTrials.gov (November 16, 2011, to April 16, 2015) to identify all terminated/withdrawn trials and reasons for termination. Logistics regression model was used to identify factors associated with early termination/withdrawal. Discontinuation rate was compared in trials with and without ICI. Results: We identified 12,875 trials (35% industry funded, 12% federal funded), of which 8.5% were prematurely terminated (5%) or withdrawn (3.5%); the main reasons were poor accrual (33%) and logistical (24%). ICI trials (n = 350) had a nonsignificant lower rate of termination or withdrawal compared with all other oncology trials (5.4% vs. 8.5%; p =.9) and were less likely to discontinue due to poor accrual (nonsignificant difference: 21% vs. 33%; p =.4). ICI trials were also less likely to discontinue compared with all other oncology drug trials (e.g., chemotherapy, targeted inhibitors, antiangiogenesis, biologics; 5.4% vs. 7.9%, respectively, nonsignificant difference). The 4-year cumulative incidence of failing to complete for reasons unrelated to toxicity or efficacy was 18% (95% confidence interval 16%–20%). There was no association between annual incidence across different tumor types or accrual goal and rate of trial termination. Conclusion: Poor accrual represents the main cause of early cancer trial termination. Premature termination/withdrawal rate was not significantly lower in ICI compared with other trials. Clinical trial completion remains a high priority and can be influenced by provider and patient factors. Implications for Practice: Clinical trial completion is critical for new cancer therapies. Premature trial termination or withdrawal is common and impairs progress. This study assessed factors of early terminated/withdrawn oncology trials, focusing on trials with immune checkpoint inhibitors (ICI), and found that poor accrual represents the main cause of early cancer trial termination. Premature termination/withdrawal rate was not significantly lower in immune checkpoint inhibitor trials compared to other trials. The discussion herein is focused on measures taken by the National Cancer Institute and other institutions to improve clinical trial accrual and prevent premature clinical trial discontinuation.
Revisión por pares
APA, Harvard, Vancouver, ISO, and other styles
2

El-Refai, Sherif M. "EXPLORING THE EFFECT OF CHRONIC INFLAMMATION ON RESPONSE TO IMMUNE CHECKPOINT INHIBITORS IN CANCER." UKnowledge, 2018. https://uknowledge.uky.edu/pharmacy_etds/82.

Full text
Abstract:
Precision medicine has allowed for the development of monoclonal antibodies that unmask the anti-tumor immune response. These agents have provided some patients durable clinical benefit. However, PD-1 and PD-L1 inhibitor therapies are effective in a small group (10-20%) of non-small cell lung cancer (NSCLC) patients when used as single-agent therapy. The approved companion diagnostic is expression of the immune cell surface molecule, programmed death ligand 1 (PD-L1), on tumors measured by immunohistochemistry (IHC). Studies in tumor biology and immune surveillance dictate that PD-1 inhibitor efficacy should depend on the level of PD-L1 expression; however, the literature has not followed with convincing evidence. The limitations of this test include timing of tissue acquisition, tumor heterogeneity, and timing of therapy relative to the expression of PD-L1. In addition, the requirement of analyzing tumor tissue biopsy samples from a patient is cumbersome. Thus, a peripheral blood biomarker that predicts efficacy of PD-1/PD-L1 inhibition would be optimal for precise and cost-effective treatment. A history of chronic inflammatory diseases may be advantageous for a cancer patient who is treated with PD-1/PD-L1 inhibitors and may allow them to then mobilize a swift immune response to tumor cells. Specific biological components of this persistent inflammation may predict PD-1 inhibitor response. We have taken a novel approach to leverage national healthcare claims data that couples patient history with response to therapy. We have identified potential peripheral blood biomarkers of response to PD-1/PD-L1 inhibitors using a combination of healthcare outcomes and molecular markers that correlate with therapeutic efficacy.
APA, Harvard, Vancouver, ISO, and other styles
3

Abdo, Mustafa [Verfasser]. "Prediction of patients’ response to immune checkpoint inhibitors in the treatment of advanced NSCLC / Mustafa Abdo." Göttingen : Niedersächsische Staats- und Universitätsbibliothek Göttingen, 2021. http://d-nb.info/1228623848/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Tannous, Désirée. "The combination of Gadolinium-based nanoparticles, radiotherapy and immune checkpoint inhibitors : a novel therapeutic opportunity for cancer treatment." Thesis, université Paris-Saclay, 2022. http://www.theses.fr/2022UPASL082.

Full text
Abstract:
Les découvertes scientifiques liées à la radiothérapie sont en progression continue et près de 60 % des patients diagnostiqués d'un cancer sont traités par radiothérapie. Cependant, ce traitement fait face à de nombreuses limitations dues à la radiorésistance et aux effets secondaires infligés sur les tissus sains. Pour surmonter ces problèmes, un intérêt particulier a été suscité sur le rôle que pourrait jouer la nanomédecine dans l'amélioration de la réponse anti-tumorale médiée par le système immunitaire. Dans ce contexte, nous avons décidé d'évaluer la capacité de la combinaison de nanoparticules de Gadolinium (AGuIX) avec les rayonnements ionisants (RI) à stimuler une réponse immunologique anti-tumorale et à augmenter l'efficacité de la radiothérapie associée à des inhibiteurs de points de contrôle immunitaires. AGuIX sont de très petites nanoparticules composées d'une matrice de polysiloxane et de chélates de gadolinium. Grâce aux propriétés magnétiques du Gadolinium, ces nanoparticules jouent le rôle d'agent de contraste, en plus de ses propriétés radiosensibilisantes, permettant ainsi un meilleur ciblage et un index thérapeutique renforcé.Nos travaux révèlent la capacité de AGuIX + RI à induire une instabilité génomique et à stimuler les voies de signalisation cellulaire immunomodulatrices. En parallèle, nous démontrons le potentiel anti-tumoral de la combinaison d'AGuIX + RI en évaluant la croissance tumorale et la survie globale à l'aide d'un modèle préclinique de souris immunocompétentes porteuses de tumeurs. Nos résultats suggèrent un effet synergique de la combinaison d'AGuIX + RI sur la croissance tumorale en stimulant le système immunitaire. Enfin, nous révélons la capacité de la combinaison d'AGuIX + RI à surmonter la résistance aux inhibiteurs de points de contrôle immunitaires. En conclusion, nos travaux montrent que la combinaison d'AGuIX + RI stimule des voies de signalisation immunomodulatrices, induit une forte réponse anti-tumorale synergique et permet de surmonter la résistance aux immunothérapies
Scientific discoveries linked to radiotherapy are in continuous progress and almost 60% of cancer diagnosed patients are treated with radiotherapy. However, radiation therapy still faces many limitations due to radioresistance and the side effects inflected on healthy tissues. To overcome these factors, a particular interest has been aroused on the role that nanomedicine could play in the improvement of immune-mediated anti-tumor response. In this context, we decided to assess the ability of the combination of Gadolinium nanoparticles (AGuIX) with ionizing radiation (IR) to stimulate an anti-tumor immunological response and to increase the effectiveness of radiotherapy combined to immune checkpoint blockers.AGuIX are very small nanoparticles composed of a polysiloxane matrix and gadolinium chelates. Thanks to the magnetic properties of gadolinium, these nanoparticles play the role of a contrast agent, in addition to its radiosensitizing properties, thus allowing a better targeting and an enhanced therapeutic index.Our work reveals the ability of the AGuIX+IR combination to induce genomic instability and to stimulate immunomodulatory cell signaling pathways in treated human and murine cancer cells. In parallel, we demonstrate the anti-tumor activity of this combination by assessing tumor growth and overall survival using a preclinical model of immunocompetent mice bearing tumors. Our results strongly demonstrate a synergistic effect of AGuIX + IR combination on tumor growth and overall survival by stimulating the immune system. Finally, we reveal the capacity of AGuIX + IR combination to overcome immune checkpoint blockers resistance.In conclusion, our work shows that the combination of AGuIX+IR stimulates immunomodulatory signaling pathways, induces a strong synergistic anti-tumor response and helps overcoming resistance to immunotherapies
APA, Harvard, Vancouver, ISO, and other styles
5

Seeber, Tonia Olivia [Verfasser]. "Primary Resistance to Immune Checkpoint Inhibitors in Patients with Metastatic Melanoma : Prognosis, Subsequent Therapies and Survival / Tonia Olivia Seeber." Tübingen : Universitätsbibliothek Tübingen, 2021. http://d-nb.info/123272582X/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Sodre, De Castro Laino Andressa. "Targeting Histone Deacetylases in Melanoma and T-cells to Improve Cancer Immunotherapy." Scholar Commons, 2016. http://scholarcommons.usf.edu/etd/6144.

Full text
Abstract:
Histone deacetylases (HDACs) are key mediators of gene expression and, thus, major regulators of cell function. As such, HDACs play a role in orchestrating tumor biology, and the use of small inhibitors targeting theses proteins is attractive for the field of cancer therapy. Indeed, several HDAC inhibitors have received FDA-approval for the treatment of malignancies, while a myriad of these compounds continue to be evaluated in clinical trials. Besides their direct impact on tumor growth, HDAC inhibitors have been shown to increase immunogenicity of cancer cells, facilitating generation of a productive immune response against tumors. Immunotherapeutic approaches take advantage of the intrinsic ability of the immune system to manifest an anti-tumor response. Mechanisms of immune escape are often developed by cancer cells, neutralizing activity of the immune system. For example, upregulation of the PD1 ligands PDL1 and PDL2 by tumor cells negatively regulates the anti-tumor functions of PD1-expressing infiltrating T-cells. Importantly, strategies targeting this inhibitory axis have shown outstanding clinical benefit for the treatment of solid and hematological malignancies. The mechanisms by which HDAC inhibitors modulate tumor and immune cells biology were explored herein. Initially, treatment of melanoma cells with pan- and class I-selective HDAC inhibitors resulted in upregulation of PDL1 and PDL2 molecules. These effects were observed in mouse and human cell lines, as well as in tumor cells resected from metastatic melanoma patients. This upregulation was robust and sustained, lasting at least 96 hours in vitro, and validated in vivo using a B16F10 syngeneic mouse model. Enhanced expression of PDL1 mediated by HDAC inhibitors was found to result from enhanced histone acetylation at the PDL1 gene promoter region. Combination therapy of HDAC inhibition and PD1 blockade was explored in the tumor setting, leading to synergistic effects in terms of reducing melanoma progression and increasing survival of B16F10 melanoma-bearing mice. These data provide a clinical rationale for combination therapy of epigenetic modifiers (e.g. HDAC inhibitors) and PD1 blockade as means to augment cancer immunotherapy, improving patient outcomes. As a second pillar of this research, the impacts of HDAC-selective inhibition were explored on immune cell biology, since the broad nature of pan-HDAC inhibitors was shown to be detrimental to T-cells in vitro and in vivo. Based on screening assay results, novel implications of treating melanoma patient T-cells ex vivo with the HDAC6-selective inhibitor ACY1215 were investigated. Treatment with this compound was unique among pan- and isotype-selective HDAC inhibitors in modulating T-cell cytokine production and showing minimal impact of T-cell viability. ACY1215 tempered Th2 cytokine production (i.e. IL-4, IL-6 and IL-10), and maintained Th1 effector cytokines (e.g. IFNγ and IL-2). Furthermore, ACY1215 increased expression of surface markers, including CD69 activation marker and ICOS co-stimulatory molecule. In addition, ACY1215 treatment enhanced accumulation of central memory T-cells during ex vivo expansion of tumor infiltrating T-cells harvested from resected tumors of metastatic melanoma patients. Importantly, ACY1215-mediated inhibition improved tumor-killing capacity of T-cells. These results highlight an unexplored ability of selective HDAC inhibitor ACY1215 to augment T-cell expansion during protocols of adoptive cell therapy. While the discoveries presented here warrant further investigation of cellular and molecular mechanisms associated with ACY1215-treated T-cells, the clinic implications are clear and rapidly translatable.
APA, Harvard, Vancouver, ISO, and other styles
7

Gehring, Svenja [Verfasser], and Ulrich M. [Akademischer Betreuer] Lauer. "A novel treatment strategy for colorectal cancer : Measles vaccine virus-induced oncolysis in combination with immune checkpoint inhibitors and NK cells / peripheral blood mononuclear cells / Svenja Gehring ; Betreuer: Ulrich M. Lauer." Tübingen : Universitätsbibliothek Tübingen, 2020. http://d-nb.info/1204421951/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Cohen, Romain. "Caractérisation phénotypique et clinique des cancers colorectaux métastatiques avec instabilité des microsatellites Clinical and molecular characterization of hereditary and sporadic metastatic colorectal cancer harbouring microsatellite instability/DNA mismatch repair deficiency Association of primary resistance to immune checkpoint inhibitors in metastatic colorectal cancer with misdiagnosis of microsatellite instability or mismatch repair deficiency status." Thesis, Sorbonne université, 2018. http://www.theses.fr/2018SORUS313.

Full text
Abstract:
L’instabilité des microsatellites (MSI) est un phénotype tumoral dû à une déficience héréditaire ou acquise du système de réparation des mésappariements de l’ADN (MMR : mismatch repair). Le phénotype MSI est retrouvé dans 5% des cancers colorectaux métastatiques (CCRm) et est un facteur prédictif positif majeur de l’efficacité des inhibiteurs de checkpoints immunitaires (ICKi). L’objectif de mon travail a été de caractériser sur le plan clinique et moléculaire les CCRm MSI, d’en évaluer les modalités diagnostiques et d’évaluer la réponse aux ICKi. Dans un 1er travail, je montre que l’histoire naturelle clinique des CCRm MSI diffère selon le mécanisme sporadique ou héréditaire de la déficience MMR (Cohen et al., Eur J Cancer 2017). Dans un 2e travail, je montre que près de 10% des CCRm détectés comme MSI/MMR-déficients en vie réelle correspondent à des faux positifs des analyses immunohistochimiques et/ou de PCR, et que ces faux positifs sont responsables de la majorité des cas de résistance primaire aux ICKi observés dans les essais cliniques (Cohen*, Hain* et al., JAMA Oncol. 2018). Après une revue de la littérature concernant le phénotype MSI, son impact dans le cadre du CCR et des ICKi, je présente les résultats des travaux développés durant ce doctorat, avant de proposer différentes perspectives à l’ère de l’immunothérapie des cancers MSI
Microsatellite instability (MSI) is a tumor phenotype linked to somatic or germline inactivating alterations of DNA mismatch repair (MMR) genes. MSI is observed in approximately 5% of metastatic colorectal cancers (mCRC) and has recently emerged as a major positive predictive biomarker for the efficacy of immune checkpoint inhibitors (ICKi) amongst mCRC patients. The objectives of my work was to clinically and molecularly characterize MSI mCRC, to evaluate the accuracy of MSI screening methods and the response to immunotherapy in the context of ICKi clinical trials. Fist, I show that sporadic and inherited MSI mCRC display distinct natural history (Cohen et al., Eur J Cancer 2017). In a second work, I show that MSI testing in routine practice is associated with almost 10% of false positives due to misinterpration of IHC and PCR assays. Moreover, these false-positives are the main cause of mCRC primary resistance to ICKi observed in clinical trials (Cohen*, Hain* et al., JAMA Oncol. 2018). After summarizing the literature concerning MSI, its consequences on CRC and immunotherapy, I present the results of the nosologic and diagnostic works developed during this doctoral thesis. Then I will go on perspectives in the context of MSI cancer
APA, Harvard, Vancouver, ISO, and other styles
9

Moya, Plana Antoine. "Recherche de biomarqueurs pronostiques dans le mélanome muqueux non opérable et/ou métastatique : Régulation traductionnelle de SOX10 par l’hexokinase 2 et modulation de l'agressivité tumorale dans le mélanome cutané Prognostic Value and Therapeutic Implications of Nodal Involvement in Head and Neck Mucosal Melanoma Evaluation of the Efficacy of Immunotherapy for Non-Resectable Mucosal Melanoma Oncologic Outcomes, Prognostic Factor Analysis and Therapeutic Algorithm Evaluation of Head and Neck Mucosal Melanomas in France Mélanomes cutanés cervico-faciaux Prognostic 18F-FDG PET Biomarkers in Metastatic Mucosal and Cutaneous Melanoma Treated with Immune Checkpoint Inhibitors Targeting PD-1 and CTLA-4." Thesis, université Paris-Saclay, 2020. http://www.theses.fr/2020UPASS069.

Full text
Abstract:
Les mélanomes muqueux sont rares avec un potentiel métastatique important. L’immunothérapie est un traitement prometteur dans ce sous-type agressif de mélanome. L’analyse de biomarqueurs de réponse à une immunothérapie anti-PD1 chez 23 patients présentant un mélanome muqueux non opérable et/ou métastatique a montré que l’activation du complexe d’initiation de la traduction, eIF4F, était fortement prédictive de cette réponse. Cette activation a été mesurée par un test de proximité entre les sous-unités eIF4E et eIF4G. Les autres marqueurs admis, tels que l’expression tumorale de PD-L1 ou les caractéristiques de l’infiltrat lymphocytaire intra-tumoral, n’ont pas de valeur pronostique significative dans cette cohorte.La glycolyse anaérobie est la voie métabolique que la plupart des cellules tumorales privilégient lors de lacancérogenèse. Ce phénomène est appelé « effet Warburg ». Au cours de la mélanomagénèse, il existe un continuum entre l’expression croissante de l’hexokinase 2 (ou HK2, première enzyme de la glycolyse) et l’agressivité tumorale. Dans cette étude, nous avons montré que l’inhibition d’expression d’HK2 (par siARN) induisait, in vitro, une diminution majeure de la migration et de l’invasion tumorales indépendamment du métabolisme glucidique ou de l’expression initiale d’HK2. Par une technique de profilage des polysomes, nous avons observé que HK2 régulait la traduction de l’ARNm de SOX10, un facteur de transcription impliqué dans l’initiation et la progression du mélanome. Nous avons alors réalisé une immunoprécipitation de l’ARN après induction de liaisons protéine-ARN par du formaldéhyde, nous permettant ainsi de démontrer que la protéine HK2 se liait à l’ARNm de SOX10
Mucosal melanoma is a rare tumor with a high metastatic potential. Immunotherapy has promising results in this aggressive subtype of melanoma. In a cohort of 23 patients with non-resectable and/or metastatic mucosal melanoma who received anti-PD1 immunotherapy, we showed that the activation of the eukaryotic translation initiation complex, eIF4F, was a strong prognostic biomarker of response. This activation was assessed with a proximity ligation assay between eIF4E and eIF4G. The other biomarkers, such as the PD-L1 tumoral expression or the characteristics of tumor-infiltrating lymphocytes, had no prognostic value in this cohort.Aerobic glycolysis is usually the main metabolic pathway in tumor cells during cancerogenesis. This specificprocess is called “Warburg effect”. During melanomagenesis, we observed a positive correlation between the expression level of hexokinase 2 (HK2, first enzyme of glycolysis) and the tumor invasiveness. In this study, we showed that inhibition of HK2 expression (by siRNA) induced, in vitro, a major decrease of migration and invasion potential independently of the basal glycolytic metabolism or HK2 expression level in the cell lines. Moreover, performing a polysome profiling analysis, we demonstrated that HK2 was regulating the translation of SOX10 mRNA, a transcription factor involved in initiation and progression of melanoma. We, then, realized an RNA immunoprecipitation in formaldehyde and showed that HK2 was an RNA-binding protein, able to interact with the SOX10 mRNA
APA, Harvard, Vancouver, ISO, and other styles
10

Rodrigues, Soraia Gonçalves Pereira. "Immune checkpoint inhibitors for the treatment of gastric cancer." Master's thesis, 2021. https://hdl.handle.net/10216/134392.

Full text
Abstract:
O cancro gástrico (GC) é o quinto cancro mais incidente e o quarto mais mortal em todo o mundo. O CG é uma doença heterogénea do ponto de vista histológico e molecular. Esta neoplasia é diagnosticada principalmente em estádios avançados da doença, onde as intervenções terapêuticas disponíveis não são eficazes. O aparecimento da imunoterapia transformou o panorama do tratamento do cancro, incluindo do GC e, atualmente, inibidores dos checkpoints imunológicos foram aprovados para o tratamento de doentes com GC recorrente ou metastático. Esta revisão resume os principais ensaios clínicos que avaliam o uso de inibidores dos checkpoints imunológicos em GC. Neste artigo destaca-se ainda o potencial da expressão de PD-L1 e da carga mutacional tumoral, bem como de aspetos característicos da classificação molecular do GC, como a instabilidade de microssatélites e a infeção pelo vírus Epstein-Barr, como biomarcadores preditivos da resposta terapêutica ao bloqueio do eixo PD-1 / PD-L1 no GC.
Gastric cancer (GC) is the fifth most incident and the fourth deadliest cancer worldwide. GC is a heterogeneous disease from the histological and molecular standpoints. This malignancy is mostly diagnosed at advanced stages of the disease, where the available therapeutic interventions are not effective. The emergence of immunotherapy has transformed the landscape of cancer treatment, including GC, and currently immune checkpoint inhibitors have been approved for the treatment of patients with recurrent/metastatic GC. This review summarizes the main clinical trials evaluating the use of immune checkpoint inhibitors in GC. It also highlights the potential of biomarkers for patient selection for GC immune checkpoint inhibition therapy, including PD-L1 expression and tumor mutational burden, and characteristics of the GC molecular classification, such as microsatellite instability status and Epstein-Barr virus infection, as predictors of response to blockade of the PD-1/PD-L1 axis.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Immune checkpoint inhibitors (ICIs)"

1

Balogh, Erin, and Sharyl J. Nass, eds. Advancing Progress in the Development of Combination Cancer Therapies with Immune Checkpoint Inhibitors. Washington, D.C.: National Academies Press, 2019. http://dx.doi.org/10.17226/25405.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ito, Fumito, and Marc Ernstoff. Immune Checkpoint Inhibitors in Cancer. Elsevier - Health Sciences Division, 2018.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Immune Checkpoint Inhibitors in Cancer. Elsevier, 2019. http://dx.doi.org/10.1016/c2016-0-05251-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ventures, Medtech. Immune Checkpoint Inhibitors: Technology and Market Forecast. Independently Published, 2020.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Immune Checkpoint Inhibitors - New Insights and Recent Progress [Working Title]. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.100958.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Dermime, Said, Maysaloun Merhi, and Taha Merghoub. Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer. Frontier Media SA, 2021. http://dx.doi.org/10.3389/978-2-88971-863-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

National Comprehensive Cancer Network® (NCCN®). NCCN Guidelines for Patients® Immunotherapy Side Effects: Immune Checkpoint Inhibitors. National Comprehensive Cancer Network® (NCCN®), 2022.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Board on Health Care Services, National Cancer Policy Forum, Sharyl J. Nass, National Academies of Sciences, Engineering, and Medicine, and Health and Medicine Division. Advancing Progress in the Development of Combination Cancer Therapies with Immune Checkpoint Inhibitors: Proceedings of a Workshop. National Academies Press, 2019.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Board on Health Care Services, National Cancer Policy Forum, Sharyl J. Nass, National Academies of Sciences, Engineering, and Medicine, and Health and Medicine Division. Advancing Progress in the Development of Combination Cancer Therapies with Immune Checkpoint Inhibitors: Proceedings of a Workshop. National Academies Press, 2019.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Board on Health Care Services, National Cancer Policy Forum, Sharyl J. Nass, National Academies of Sciences, Engineering, and Medicine, and Health and Medicine Division. Advancing Progress in the Development of Combination Cancer Therapies with Immune Checkpoint Inhibitors: Proceedings of a Workshop. National Academies Press, 2019.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Immune checkpoint inhibitors (ICIs)"

1

Zarifa, Abdulrazzak, Juan Lopez-Mattei, Nicolas Palaskas, Cezar Iliescu, Jean-Bernard Durand, and Peter Y. Kim. "Immune Checkpoint Inhibitors (ICIs)-Related Cardiotoxicity." In Advances in Experimental Medicine and Biology, 277–85. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-41008-7_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Arora, Sandeep, Saurabh Gupta, and Nidhi Garg. "Immune Checkpoint Inhibitors." In Metastatic Diseases, 207–24. Boca Raton: Apple Academic Press, 2021. http://dx.doi.org/10.1201/9781003043249-14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Lau, Keith C. K., Benson Weyant, and Carlos Cervera. "Immune Checkpoint Inhibitors." In Infectious Complications in Biologic and Targeted Therapies, 233–51. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-11363-5_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Palaskas, Nicolas L., Eric H. Yang, and Tomas G. Neilan. "Immune Checkpoint Inhibitor (ICI)-Associated Myocarditis." In Atlas of Imaging in Cardio-Oncology, 27–37. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-70998-3_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Zarifa, Abdulrazzak, Juan Lopez-Mattei, Nicolas L. Palaskas, Cezar Iliescu, Jean-Bernard Durand, and Peter Y. Kim. "Immune Checkpoint Inhibitor (ICI)-Related Cardiotoxicity." In Advances in Experimental Medicine and Biology, 377–87. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-79308-1_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Gerber, Peter Arne. "Oncology: Immune Checkpoint Inhibitors." In Cutaneous Drug Hypersensitivity, 155–59. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-82743-4_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Mahdavi Sharif, Pouya, Mahsa Keshavarz-Fathi, and Nima Rezaei. "Biomarkers for Immune Checkpoint Inhibitors." In Cancer Immunology, 449–63. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-50287-4_25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Tian, Yun, Hamzah Abu-Sbeih, and Yinghong Wang. "Immune Checkpoint Inhibitors-Induced Colitis." In Advances in Experimental Medicine and Biology, 151–57. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-030-02505-2_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Tian, Yun, Hamzah Abu-Sbeih, and Yinghong Wang. "Immune Checkpoint Inhibitors-Induced Hepatitis." In Advances in Experimental Medicine and Biology, 159–64. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-030-02505-2_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

D’Angelo, Sandra P., and Ciara M. Kelly. "Immune Checkpoint Inhibitors in Sarcoma." In Immunotherapy of Sarcoma, 125–37. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-93530-0_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Immune checkpoint inhibitors (ICIs)"

1

Kesireddy, Meghana, Apar Ganti, Alissa Marr, and Makayla Schissel. "1245 Safety and efficacy of immune checkpoint inhibitors (ICIs) in patients with pre-existing organ dysfunction." In SITC 37th Annual Meeting (SITC 2022) Abstracts. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/jitc-2022-sitc2022.1245.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

AO, Georgina Long, Tracy Tang, Abraham Apfel, David Paulucci, Scott Chasalow, Daniel Tenney, Gina Fusaro, et al. "608 Predicting primary resistance and exploring mechanisms in patients with advanced melanoma treated with immune checkpoint inhibitors (ICIs)." In SITC 37th Annual Meeting (SITC 2022) Abstracts. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/jitc-2022-sitc2022.0608.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Shah, Neil J., Ghassan AL-Shbool, Matthew Blackburn, Michael Cook, William J. Kelly, Anas Belouali, Sebastian Ochoa, et al. "Abstract 3230: Safety and efficacy of immune checkpoint inhibitors (ICIs) in patients with HIV, hepatitis B, or hepatitis C viral infections." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-3230.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Wang, Xinan, Biagio Ricciuti, Joao V. Alessi, Tom Nguyen, Mark M. Awad, Xihong Lin, Bruce E. Johnson, and David C. Christiani. "Abstract 370: Smoking history as an independent predictor for immune checkpoint inhibitors (ICIs) in metastatic non-small cell lung cancer (NSCLC)." In Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-370.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Shah, Neil J., Ghassan AL-Shbool, Matthew Blackburn, Michael Cook, William J. Kelly, Anas Belouali, Sebastian Ochoa, et al. "Abstract 3230: Safety and efficacy of immune checkpoint inhibitors (ICIs) in patients with HIV, hepatitis B, or hepatitis C viral infections." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-3230.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Barreto, Maria Eduarda Slhessarenko Fraife, Arthur Malzyner, Nelson Hamerschlak, Maurício Muradian, Alessandra Delavance, and Lívia Almeida Dutra. "Myasthenia gravis, myositis, myocarditis and anti-titin antibodies after Nivolumab/Ipilimumab: response with plasmapheresis." In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.379.

Full text
Abstract:
Context: Severe neurological manifestations following use of immune checkpoint inhibitors (ICIs) occur in 0.93% of patients, and together with cardiac toxicity have the higher lethality. Myasthenia gravis (MG) and polymyositis (PM) are rare, and treatment includes discontinuation of the immunotherapy, corticosteroids, and intravenous immunoglobulin (IVIG), with occasional use of plasmapheresis (PLEX). Biomarkers are not consistently reported. We report the case of a patient with MG, PM and myocarditis after ICI, with positive anti-titin antibodies and response to plasmapheresis. Case report: 81-year-old male developed ascending, subacute, progressive tetraparesis, dysphagia, ophthalmoparesis, and respiratory failure 2 weeks after second cycle of nivolumab/ipilimumab for metastatic melanoma. Physical examination showed: globally reduced strength, hypoactive reflexes, bilateral sixth nerve palsy and bilateral semi-ptosis. Prostigmine test was positive and electroneuromyography was compatible with myopathy. Labs revealed CPK 4000 U/L, troponin 9000U/L, autoimmune myositis panel negative, anti-titin antibodies (described in paraneoplastic MG and associated with severity) positive and cardiac MRI without fibrosis. Clinical picture was compatible with MG and PM with cardiac involvement. He received methylprednisolone and six PLEX sessions, with complete recovery. Four months after treatment, he developed cognitive impairment and large B-cell lymphoma (ICI complication). Conclusions: PM and MG may occur after ICI, especially in the first cycles, and anti-titin may be a biomarker of severity in these patients. Although guidelines recommend adding IVIG or PLEX in refractory or severe cases, PLEX may be first choice, especially if multiple ICI are present.
APA, Harvard, Vancouver, ISO, and other styles
7

Funakoshi, Tomohiro, Hyman Muss, and Stergios Moschos. "Abstract A159: Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A meta-analysis of randomized controlled trials." In Abstracts: CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival; September 16-19, 2015; New York, NY. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/2326-6074.cricimteatiaacr15-a159.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Hsieh, Yi-Lin, Pei-Ning Yu, Yi-Hua Jan, Meng-Shao Lai, Woei-Fuh Wang, De-Wei Zhuo, Shu-Jen Chen, Jen-Hao Cheng, Kien Thiam Tan, and Yu-Li Su. "Abstract 3177: Panel-derived tumor mutational burden (TMB) is associated with the response to the immune checkpoint inhibitors (ICIs) in urothelial cancers." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-3177.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Crequit, Perrine, Alexandre Vivot, Raphael Porcher, and Jacques Cadranel. "Benefit of immune checkpoint inhibitors (ICIs) for second-line treatment of advanced non-small cell lung cancer (NSCLC) using restricted mean survival time (RMST)." In ERS International Congress 2018 abstracts. European Respiratory Society, 2018. http://dx.doi.org/10.1183/13993003.congress-2018.pa2807.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Singh, Neeraj, Smita Agrawal, and Babu Narayanan. "531 Identifying genetic factors for resistance and response to immune checkpoint inhibitors (icis) in advanced non-small cell lung cancer (nsclc) patients using real-world data." In SITC 37th Annual Meeting (SITC 2022) Abstracts. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/jitc-2022-sitc2022.0531.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Immune checkpoint inhibitors (ICIs)"

1

Tinker, Anna V., Neesha C. Dhani, Prafull Ghatage, Deanna McLeod, Vanessa Samouëlian, Stephen A. Welch, and Alon D. Altman. Immune Checkpoint Inhibitors in Pretreated Metastatic Endometrial Cancer. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, January 2023. http://dx.doi.org/10.37766/inplasy2023.1.0038.

Full text
Abstract:
Review question / Objective: Efficacy and safety of immune checkpoint inhibitors alone or in combination with tyrosine kinase inhibitors in patients with pretreated advanced, persistent, or recurrent metastatic endometrial cancer. Condition being studied: Advanced, persistent, or recurrent metastatic endometrial cancer. Study designs to be included: Non-randomized studies of monotherapy in populations selected for relevant biomarkers such as MMR, microsatellite stability, and PD-L1 expression status and randomized trials of ICI combinations in unselected patients.
APA, Harvard, Vancouver, ISO, and other styles
2

Peng, Yinglong, Jinwei Chen, Ziyan Wang, Yihui Cao, and Jie Zhao. A Systematic Review and meta-analysis of the efficacy of immunotherapy in the treatment of non-small cell lung cancer. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, June 2022. http://dx.doi.org/10.37766/inplasy2022.6.0094.

Full text
Abstract:
Review question / Objective: This study aimed to compare the effectiveness of different ICIs in the treatment of NSCLC, and to provide a theoretical basis for clinical selection of different regimens. Condition being studied: Immunotherapy is a relatively new treatment method for non-small cell lung cancer (NSCLC), and clinical studies confirmed that immune checkpoint inhibitors (ICIs) showed prominent efficacy in the treatment of NSCLC patients. This study aimed to compare the effectiveness of different ICIs in the treatment of NSCLC, and to provide a theoretical basis for clinical selection of different regimens.
APA, Harvard, Vancouver, ISO, and other styles
3

Crocetto, Felice, Carlo Buonerba, Luca Bardi, Antonio Verde, Simone Cilio, Biagio Barone, Gabriele Barbato, et al. Cardiovascular adverse events in patients with kidney cancer receiving combination of angiogenesis inhibitors plus immune checkpoint inhibitors vs. angiogenesis inhibitors vs. immune checkpoint inhibitors: a network analysis of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, December 2021. http://dx.doi.org/10.37766/inplasy2021.12.0060.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Yang, Kaili. Retreatment with immune checkpoint inhibitors in solid tumors: a systematic review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, April 2020. http://dx.doi.org/10.37766/inplasy2020.4.0041.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Wang, He, Jun Chen, Xiaoling Wang, and Jun Dang. Neoadjuvant immune checkpoint inhibitor in combination with chemotherapy or chemoradiotherapy in resectable esophageal cancer: A systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, June 2022. http://dx.doi.org/10.37766/inplasy2022.6.0052.

Full text
Abstract:
Review question / Objective: It remains unclear whether addition of immune checkpoint inhibitor (ICI) to neoadjuvant chemoradiotherapy (nCRT) or neoadjuvant chemotherapy (nCT) can increase antitumor efficacy in resectable esophageal cancer (EC). we performed the systematic review and meta-analysis to assess antitumor efficacy and safety of nICRT and nICT, and made a comparison with nCRT and nICT. We used pathological complete response (pCR) as the primary outcomes of interest. Condition being studied: Initial findings from a number of phase 1 or 2 trials have supported the tolerability and/or antitumor efficacy of ICI plus nICRT (nICRT) and nICT (nICT). However, the superiority of this combination strategy remains uncertain due to lack of randomized control trials (RCTs) with long-term outcomes. Moreover, there are still outstanding questions such as the selection of nICRT or nICT, the ideal predictive biomarkers, and timing of surgical resection.
APA, Harvard, Vancouver, ISO, and other styles
6

Yao, Jiannan, Manyu Li, and Guangyu An. Dermatolagic adverse events from immune-checkpoint inhibitors combination therapy:a systematic review and meta analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2020. http://dx.doi.org/10.37766/inplasy2020.5.0068.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Jiang, Juan, Xiongmin Guo, Chengping Hu, and Jiayi Liu. Incidence of active tuberculosis after the use of immune checkpoint inhibitors in cancer patients. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, July 2022. http://dx.doi.org/10.37766/inplasy2022.7.0078.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Wang, Yan, and Qunqin Ni. Prognostic and clinicopathological significance of systemic immune-inflammation index in cancer patients receiving immune checkpoint inhibitors: a meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, January 2023. http://dx.doi.org/10.37766/inplasy2023.1.0018.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Chen, Baoqing, Chen Yang, Qiaoqiao Li, Mihnea Dragomir, and George A. Calin. Effects of proton pump inhibitors in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, October 2020. http://dx.doi.org/10.37766/inplasy2020.10.0088.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Gonzalez, Brian, Sarah Eisel, Kristine Bowles, Aasha Hoogland, Brian James, Brent Small, Susan Sharpe, et al. Protocol: Meta-Analysis of Quality of Life in Cancer Patients Treated with Immune Checkpoint Inhibitors. INPLASY - International Platform of Registered Systematic Review Protocols, April 2020. http://dx.doi.org/10.37766/inplasy2020.4.0203.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Immune checkpoint inhibitors (ICIs)' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography